The Dupont Merck Pharmaceutical Company

Dupont Pharmaceuticals Company

E.i. Dupont De Nemours and Company

Leonard Cook

Engelbert Ciganek

The invention relates to a method of treating alcoholism and alcohol dependence in a mammal comprising administering to the mammal a therapeutically effective amount of a synergistic combination of: (i) at least one opioid antagonist, and (ii) at least one selective serotonin reuptake inhibitor. The invention also relates to compositions and kits containing the same.

Combination of an opioid antagonist and a selective serotonin reuptake

The invention relates to a method of treating psychosis in a mammal which comprises administering to the mammal an effective amount of a dopamine receptor antagonist antipsychotic and a sigma receptor antagonist having greater affinity for sigma receptors than for dopamine receptors, in an amount effective to selectively enhance the antipsychotic effects of the dopamine receptor antagonist relative to the adverse side effects of the dopamine receptor antagonist.

Use of sigma receptor antagonists to enhance the effects of

The invention relates to a method of treating cocaine abuse or addiction in a mammal which comprises administering to the mammal an effective amount of a sigma receptor antagonist lacking or having relatively weak dopamine receptor-blocking activity, to reduce the pharmacological effects of the cocaine.

Use of sigma receptor antagonists for treatment of cocaine abuse

The invention relates to a method of treating drug abuse or addiction involving amphetamine or amphetamine-related drugs with pharmacological effects similar to amphetamine in a mammal which comprises administering to the mammal an effective amount, to reduce the pharmacological effects of the amphetamine or amphetamine-related drug, of certain piperidine sigma receptor antagonists.

Use of sigma receptor antagonists for treatment of amphetamine abuse

Known and novel 4-aryl-4-piperidinecarbinols and heterocyclic analogs are useful as analgesics. Also provided are novel pyrrolidinecarbinols and hexahydroazepine carbinols which are useful as analgesics, antidepressants and, in some cases, as anorectic agents.

4-aryl-4-piperidine (or pyrrolidine or hexahydroazepine) carbinols and

Known and novel 4-aryl-4-piperidinecarbinols and heterocyclic analogs are useful as analgesics. Also provided are novel pyrrolidinecarbinols and hexhydroazepine carbinols which are useful as analgesics, antidepressants and, in some cases, as anorectic agents.

Growing community of inventors

Newark, DE, United States of America

Leonard Cook